Detection of human papillomavirus (HPV) 16-specific CD4+ T-cell immunity in patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment.
about
VIN usual type-from the past to the futureTherapy of human papillomavirus-related diseaseThe simultaneous ex vivo detection of low-frequency antigen-specific CD4+ and CD8+ T-cell responses using overlapping peptide pools.Imiquimod for treatment of vulvar and vaginal intraepithelial neoplasia.More than a decade on: review of the use of imiquimod in lower anogenital intraepithelial neoplasia.Human Immunodeficiency Virus and Human Papilloma Virus - why HPV-induced lesions do not spontaneously resolve and why therapeutic vaccination can be successful.The TLR7 agonist imiquimod induces anti-cancer effects via autophagic cell death and enhances anti-tumoral and systemic immunity during radiotherapy for melanoma.Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia.A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3.Human papillomavirus deregulates the response of a cellular network comprising of chemotactic and proinflammatory genes.Clinical and immunological response to photodynamic therapy in the treatment of vulval intraepithelial neoplasia.Therapeutic options for treatment of human papillomavirus-associated cancers - novel immunologic vaccines: ADXS11-001.Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses.Association between toll-like receptor expression and human papillomavirus type 16 persistence.Anti-HPV16 E2 protein T-cell responses and viral control in women with usual vulvar intraepithelial neoplasia and their healthy partners.Sequential cisplatin therapy and vaccination with HPV16 E6E7L2 fusion protein in saponin adjuvant GPI-0100 for the treatment of a model HPV16+ cancer.Immunoprevention of human papillomavirus-associated malignanciesExpression of nucleic acid-sensing Toll-like receptors predicts HPV16 clearance associated with an E6-directed cell-mediated responseGenerating HPV specific T helper cells for the treatment of HPV induced malignancies using TCR gene transfer.Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens.Immunotherapy of human papilloma virus induced diseaseIntravaginal immunization of mice with recombinant Salmonella enterica serovar Typhimurium expressing human papillomavirus type 16 antigens as a potential route of vaccination against cervical cancerTherapeutic use of Aldara in chronic myeloid leukemia.Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions.Reversal of human papillomavirus-specific T cell immune suppression through TLR agonist treatment of Langerhans cells exposed to human papillomavirus type 16.Therapeutic vaccines against human papillomavirus and cervical cancer.Management of anal squamous intraepithelial lesions.Human papillomavirus 16 E2-, E6- and E7-specific T-cell responses in children and their mothers who developed incident cervical intraepithelial neoplasia during a 14-year follow-up of the Finnish Family HPV cohort.Treatment failure in patients with HPV 16-induced vulvar intraepithelial neoplasia: understanding different clinical responses to immunotherapy.Toll-like receptors in human papillomavirus infection.Anal intraepithelial neoplasia and squamous cell carcinoma in HIV-infected adults.The Interaction Between Human Papillomaviruses and the Stromal Microenvironment.Expression of coinhibitory receptors on T cells in the microenvironment of usual vulvar intraepithelial neoplasia is related to proinflammatory effector T cells and an increased recurrence-free survival.Intraepithelial macrophage infiltration is related to a high number of regulatory T cells and promotes a progressive course of HPV-induced vulvar neoplasia.Antigen design enhances the immunogenicity of Semliki Forest virus-based therapeutic human papillomavirus vaccines.Alterations in classical and nonclassical HLA expression in recurrent and progressive HPV-induced usual vulvar intraepithelial neoplasia and implications for immunotherapy.Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy.Non-responders to topical imiquimod followed by vaccination therapy in VIN patients may be due to the level of IL10.The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assaysReduced local immunity in HPV-related VIN: expression of chemokines and involvement of immunocompetent cells.
P2860
Q26865303-06D173E7-07A8-47A3-97D8-242F672D3613Q27007473-BEE0F88D-AE79-40D8-B1D6-37EBB0A1D2E5Q30528191-2A7A973F-DDE1-4937-9464-655CB39223A8Q33316616-C1C8F92B-5FE2-4E45-A01B-154A09605D1FQ33520407-4D6D7009-BFA3-4B88-BBAD-8E18E3390B4CQ33574329-A6D099F9-887C-4149-B36F-191F3E59EC33Q33648709-E9CBCD99-F214-4F19-8CF8-A3F3349CED4FQ33783092-9CF8B7BC-7BA4-4630-A0D0-DEC65B632F1EQ33834057-BB942ED6-A6E6-4F7F-9264-1879C6420B25Q33851664-0AD2BCE4-1100-455F-ADF4-67753601DF1CQ33873808-30F06EA6-ED68-47E8-8E3C-44BCCA4DF86FQ33908553-B8089D8E-2BC9-407C-AA26-630A85E9766FQ33977826-BEAD2D55-F98F-4245-B1CE-1571F076B09BQ34187046-8E47C557-AC6C-4D44-AD8B-F0FB359B3084Q34270902-210565C3-5E84-4322-871F-4A5E240BA76AQ34822738-F1ED21AC-4C27-4E5E-B37B-D83D022C0AAFQ35044376-410C15FB-0ED4-4C50-87F3-8DA970917146Q35164128-213BA0D8-28FB-4CAF-9A7F-2F68C6E73D06Q35221732-501E1633-B8D5-4081-A2EC-18565910EC56Q35901282-F2C409E6-3073-4832-AE13-5243500851D2Q36541008-864E8686-741B-4266-B0E0-FB942E49165BQ36593956-D4E0B97B-4F6D-4316-A160-5A4EDF4883C3Q36718548-6A130A46-29F0-4B51-84FB-3AED8F92E824Q36987072-A1FF83BF-FF15-45F0-9C48-F17FC3B06C6AQ37349884-653828A0-5F7B-49E2-8639-CFFF416FE652Q37418916-B03B57FD-A4B2-4B8B-BADE-871635D0FDBBQ37427836-7E7E8EE0-E448-4A0D-AFD4-4E8F65CDB9E3Q37593170-4034FB3C-2891-4C38-B8A3-FFBF6E9C15DEQ38036688-55C536B5-8A1A-42CA-8DBE-4840F53A7389Q38084160-1D3F9AC7-EE2F-4E41-8FFD-392B44D92AF9Q38134426-DE315D1E-D9C0-45A0-8530-25659C02042BQ40444191-4C4772D7-3022-414C-851F-C05421C3133AQ41739849-2973680F-F7AB-4AF7-A911-75E43781E445Q41739878-C306BFCC-1C4C-4F97-9456-59760C3A90E8Q42155977-34272E33-63C2-44DB-961D-CBCDC571EA30Q42243834-857461B3-D38E-4462-B0CA-02A9DD9014B7Q42378527-D252F901-F24F-4031-BD3C-77DF441680BAQ42426482-948CA878-5D0D-4578-8FFA-34C49C467774Q42859721-B5F02E0E-3C19-4A4A-9B72-DAF98DA2F0F8Q46434837-518C9BBE-37C4-4CA2-8F06-19826F464620
P2860
Detection of human papillomavirus (HPV) 16-specific CD4+ T-cell immunity in patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Detection of human papillomavi ...... impact of imiquimod treatment.
@en
type
label
Detection of human papillomavi ...... impact of imiquimod treatment.
@en
prefLabel
Detection of human papillomavi ...... impact of imiquimod treatment.
@en
P2093
P1476
Detection of human papillomavi ...... impact of imiquimod treatment.
@en
P2093
Claudia Heijmans-Antonissen
Cornelis J M Melief
Jan W Drijfhout
Kitty M C Kwappenberg
Manon van Seters
Marc van Beurden
Mariëtte I E van Poelgeest
Rienk Offringa
Sjoerd H van der Burg
Theo J M Helmerhorst
P304
P356
10.1158/1078-0432.CCR-05-0616
P407
P50
P577
2005-07-01T00:00:00Z